A scalable hub-and-spoke engine for global drug development
Our Approach
K2 Therapeutics is a biotech company built for global impact, with search and development capabilities unconstrained by modality or geography. We identify the world’s most innovative assets and translate them into great medicines through a disciplined development approach and lead by experienced drug developers. Our focus is on high-potential first- and best-in-class assets with meaningful potential for patient impact worldwide.
Advance programs through clinical proof of concept with disciplined execution and early attention to manufacturing, translational science, and commercial potential.
Hub-and-spoke efficiency at scale
Centralized strategy and leadership combined with parallel, distributed development across multiple assets to drive efficiency, focus, and portfolio diversification.
Cross-regional collaboration for global-ready evidence
Cross-regional clinical execution across major geographical markets delivers globally relevant evidence, early derisking, and accelerates regulatory outcomes.
ProgramIndicationDiscoveryIND-enablingPhase IPhase II
KTT-001
Solid Tumor
KTT-001 is a cell therapy targeting PRAME for the treatment of cutaneous melanoma and synovial sarcoma. Designed to address key oncogenic pathways in solid tumors, KTT-001 aims to deliver potent efficacy and improved clinical outcomes for patients.
KTT-002
Solid Tumor
KTT-001 is a cell therapy targeting PRAME for the treatment of cutaneous melanoma and synovial sarcoma. Designed to address key oncogenic pathways in solid tumors, KTT-001 aims to deliver potent efficacy and improved clinical outcomes for patients.
KTT-003
Solid Tumor
KTT-001 is a cell therapy targeting PRAME for the treatment of cutaneous melanoma and synovial sarcoma. Designed to address key oncogenic pathways in solid tumors, KTT-001 aims to deliver potent efficacy and improved clinical outcomes for patients.
KTT-004
Solid Tumor
KTT-001 is a cell therapy targeting PRAME for the treatment of cutaneous melanoma and synovial sarcoma. Designed to address key oncogenic pathways in solid tumors, KTT-001 aims to deliver potent efficacy and improved clinical outcomes for patients.